Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer by Lange, Ethan M. et al.
Assessing the Cumulative Contribution of New and Established 
Common Genetic Risk Factors to Early-Onset Prostate Cancer
Ethan M. Lange1,2,3, Jessica V. Ribado1, Kimberly A. Zuhlke4, Anna M. Johnson4, Gregory 
R. Keele1, Jin Li1, Yunfei Wang5, Qing Duan1, Ge Li6, Zhengrong Gao6, Yun Li1,2, Jianfeng 
Xu6,*, S. Lilly Zheng6,*, and Kathleen A. Cooney4,7
1Department of Genetics, University of North Carolina, Chapel Hill, NC
2Department of Biostatistics, University of North Carolina, Chapel Hill, NC
3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
4Department of Internal Medicine, University of Michigan, Ann Arbor, MI
5Center for Translational Science, Children’s National Medical Center, George Washington 
University, Washington, DC
6Center for Genomics and Personalized Medicine Research, Wake Forest University, Winston-
Salem, NC
7Department of Urology, University of Michigan, Ann Arbor, MI
Abstract
Background—We assessed the evidence for association between 23 recently reported prostate 
cancer (PCa) variants and early-onset PCa and the aggregate value of 63 PCa variants for 
predicting early-onset disease using 931 unrelated men diagnosed with PCa prior to age 56 years 
and 1126 male controls.
Methods—Logistic regression models were used to test the evidence for association between the 
23 new variants and early-onset PCa. Weighted and unweighted sums of total risk alleles across 
these 23 variants and 40 established variants were constructed. Weights were based on previously 
reported effect size estimates. Receiver operating characteristic curves and forest plots, using 
defined cut-points, were constructed to assess the predictive value of the burden of risk alleles on 
early-onset disease.
Results—Ten of the 23 new variants demonstrated evidence (p < 0.05) for association with early-
onset PCa, including four that were significant after multiple test correction. The aggregate burden 
of risk alleles across the 63 variants was predictive of early-onset PCa (Area Under Curve = 0.71 
using weighted sums), especially in men with a high burden of total risk alleles.
Conclusions—A high burden of risk alleles is strongly associated with early-onset PCa.
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Impact—Our results provide the first formal replication for several of these 23 new variants and 
demonstrate that a high burden of common-variant risk alleles is a major risk factor for early-onset 
PCa.
Keywords
early-onset prostate cancer; GWAS; aggregate risk
Introduction
Prostate cancer (PCa) is the second leading cause of cancer mortality in men in the United 
States. In 2014, it is estimated that 233,000 men would be diagnosed with PCa and 29,480 
men would die from the disease (1). The major recognized risk factors for PCa are 
increasing age, African ancestry, and positive family history.
Approximately 10% of men diagnosed with PCa in the United States are diagnosed with the 
disease prior to age 56 years (1). Men with early-onset PCa are more likely to be 
aggressively treated for their disease and more likely to die from their disease compared to 
men diagnosed with PCa later in life with similar clinical characteristics (2-4). As with most 
cancers, early intervention in men that need it can significantly increase the rate of survival. 
Given the controversy surrounding prostate-specific antigen (PSA) testing, identifying 
subsets of men that would most likely benefit from early screening would have a major 
impact on the successful treatment of the disease. Early-onset disease is also an indicator for 
heritable disease (2,4,5). An important question is whether we can use the cumulative 
information across associated variants to reasonably predict who is most likely to be 
diagnosed with early-onset PCa.
To date, genome-wide association studies (GWAS), including primarily older men with PCa, 
have identified more than 60 distinct common loci with modest effects associated with the 
disease in men of European descent, including 23 new loci identified using 19,662 PCa 
cases and 19,715 controls included in the PRACTICAL consortium (6-20). Several studies 
have demonstrated the importance of the previously established common variants to early-
onset and familial PCa (12,21-25). Herein, we first test whether these 23 new variants are 
associated with early-onset PCa (20). We then assess the aggregate value of these 23 new 
variants, aggregate value of these new variants plus 40 established variants, and the added 
value of including information from these 23 new variants to the overall burden of risk 
alleles from the 40 established variants in predicting early-onset PCa. We demonstrate that 
the total risk-allele burden across PCa GWAS variants can be useful for identifying a subset 
of men with substantially increased risk for early-onset disease.
Materials and Methods
Study Samples
This study includes 931 unrelated early-onset PCa cases (diagnosed prior to age 56 years) of 
European descent from the University of Michigan Prostate Cancer Genetics Project (UM-
PCGP). Descriptive information about the cases is presented in Table 1. The average age of 
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PCa diagnosis in these 931 cases was 49.7 years. Approximately 62% (576/931) of the cases 
had a reported first or second degree relative with PCa. All UM-PCGP subjects provided 
written informed consent to participate in the study. The protocol and consent documents 
were approved by Institutional Review Board at the University of Michigan Medical School.
Publically available unrelated male controls with GWAS variant data were selected from 
Illumina’s iControlDB database (n = 1126) (26). Controls were selected to have European 
reported ancestry and genotype data generated from a GWAS commercial platform similar 
to the platform used in UM-PCGP cases. Limited descriptive information, including age, 
gender and ancestry, on selected iControlDB subjects can be obtained from the Illumina 
website. Illumina iControls have not been screened for PCa.
Genotyping
Nine-hundred-thirty-eight European American UM-PCGP early-onset PCa cases were 
genotyped at Wake Forest University using the Illumina HumanHap 660W-Quad v1.1 
BeadChip. The iControlsDB subjects were genotyped previously using the Illumina 
HumanHap550v1 or HumanHap550v3 commercial genotyping platforms.
Statistical Analyses
Initial genotyping quality control (QC) methodology was uniformly applied to all GWAS 
variants and samples (see Lange et al. (21) for details). Subjects missing >5% of variant 
genotyping calls across all GWAS variants were excluded from consideration. European 
ancestry for all subjects, including controls, was verified using the software ADMIXTURE 
(27); subjects with apparent misidentified ancestry or mixed ancestry were also removed 
from the study. Principal component analysis was also performed using the software 
Eigenstrat (28) on the combined sample of cases and controls using a linkage-disequilibrium 
(LD) pruned set of GWAS variants common across genotyping platforms for UM-PCGP 
cases and Illumina iControls.
We performed genotype imputation on the combined case-control sample to obtain genotype 
data on the 63 variants reported to be associated with PCa in Eeles et al. (20) and Goh et al. 
(29) using the software package MaCH (30,31). Genotype imputation was performed, 
separately, including variants from HapMap Phase II (CEU reference samples), HapMap 
Phase III (CEU + TSI reference samples) and the 1000 Genomes Project (Chromosome X 
only using all reference samples). For the autosomal variants, preference was given to Phase 
III imputation results when a variant was successfully imputed using both Phase II and 
Phase III HapMap samples. To reduce any possible bias in imputed genotype assignments 
due to different coverage of variants in the case and control participants, only variants that 
were successfully genotyped in >98% of both the cases and controls were included in the 
target panel prior to genotype imputation.
Logistic regression models, implemented in Mach2dat (31), were constructed to test the 
association between early-onset PCa and each of the 23 newly reported PCa variants using 
entirely imputed genotype data, scored as dosage values (expected number of copies of the 
minor alleles). The logistic regression models included covariate adjustment for the first 10 
principal components derived from the GWAS data. A Bonferroni-corrected significance 
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threshold for a one-sided test (one-sided p<0.0022), with requirement the direction of effect 
was consistent with the previous report, was applied to maintain an overall type I error rate 
of 0.05.
To assess the cumulative burden of the 23 recently identified variants on early-onset PCa, we 
estimated the total number of risk alleles each subject carries. The risk allele for each variant 
was defined as the allele associated with increased risk of PCa in Eeles et al. (20). For each 
subject, we calculated two risk scores, one based on the unweighted sum of risk alleles and 
the other based on a weighted sum, with the weight given to each variant risk allele equal to 
the natural logarithm of the corresponding variant’s reported odds ratio. For all variants, we 
used imputed genotype data, even if the variant was directly genotyped, to minimize the 
impact of any missing data on risk allele counts. We assessed, using t-tests, whether the 
unweighted total number of risk alleles was associated with PCa. We repeated these analyses 
for 40 previously established PCa variants for populations of European descent summarized 
in Goh et al. (29) (see Supplementary Table 1 for variant identities and their respective 
imputation quality). The individual association results for these 40 variants in UM-PCGP 
subjects have been reported previously (21). Finally, we calculated weighted and unweighted 
totals of risk alleles across all 63 variants.
To assess the relative ability to correctly classify subjects (with respect to case-control 
status), we constructed receiver operating characteristic (ROC) curves and calculated the 
corresponding area under the curves (AUC) for weighted and unweighted aggregate risk 
allele counts for the 23 new PCa variants, 40 established PCa variants and the set of 63 total 
PCa variants. We then focused on the tails of the weighted and unweighted risk-allele sum 
counts and ranked subjects with regard to total number risk alleles, independent of disease 
status.
We additionally hypothesized that there was a subset of men with relatively extreme values 
of total risk-allele burden that could have their disease more accurately predicted than men 
with total risk-allele counts in the middle of the corresponding total risk-allele count 
distribution. Specifically, we performed two separate categorizations of all subjects based on 
the distribution of total risk alleles in controls. In the first categorization, subjects were 
assigned to a decile grouping based on their total risk allele count using cutoff values 
defined by the observed total-risk-score values in controls (e.g. the highest decile group 
would include cases and controls with observed total risk scores greater than 90% of the 
total risk scores observed in the controls). For each decile grouping, we calculated the odds 
ratios (ORs) comparing the proportions of cases and controls between the corresponding 
decile grouping and the lowest decile grouping (the reference group). In the other 
categorization scheme, we split cases and controls into two groupings defined by total-risk-
allele threshold values across a range of percentiles cut-points (lower 2.5%, 5%, 10%, 25%, 
50%, 75%, 90%, 95%, 97.5%) defined by the controls. For each percentile cut-point, we 
compared the distributions of cases and controls between the participant groupings defined 
by the percentile cut-point. These contingency-table-based analyses were performed using 
both weighted and unweighted risk-allele counts for the 23 new variants, 40 established 
variants and combined set of 63 variants.
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Results
Ten out of 23 variants recently reported (20) achieved at least nominally significant evidence 
(one-sided p<0.05; direction of effect consistent with prior report) for association with early-
onset PCa, including rs3771570 (p=0.032), rs7611694 (p=0.014), rs1270884 (p=0.0028), 
rs8008270 (0.025), rs7241993 (0.0023), rs2405942 (p=0.011), rs42445739 (p=3.0×10-5), 
rs3096702 (p=0.0018), rs2273669 (p=8.6×10-4) and rs1933488 (p=0.0011) (Table 2). The 
latter four variants were significantly associated with PCa after accounting for multiple 
testing (one-sided p<0.0022) (Table 2). Of the remaining 13 variants that did not minimally 
achieve nominal significance, only three (rs1894292, rs7141529 and rs11650494) had a 
direction of effect that was inconsistent with the discovery study.
Early-onset PCa cases had significantly more estimated total risk alleles than unscreened 
controls across these 23 variants (PCa cases: unweighted mean=21.61, se=0.10, 
median=21.70; controls: unweighted mean=20.69, se=0.09, median=20.55; p-diff = 
2.0×10-12). Adding in the 40 established PCa variants, early-onset cases carried 58.02 
(se=0.16, median=57.98) and controls carried 54.49 (se=0.15, median=54.64) risk alleles on 
average (p-diff=8.9×10-59) across all 63 variants. Overlapping histograms plotting the 
distributions of the unweighted and weighted sums of risk alleles for cases and controls 
across the 23 new PCa variants and 63 total PCa variants are presented in Supplementary 
Figures 1 and 2, respectively.
The aggregate burden of the risk alleles across the new variants alone provided a poor ability 
to discriminate between cases and controls (AUC=0.59 for both weighted and unweighted 
sums; Figure 1). The predictive value was only slightly higher when restricting the burden of 
risk alleles to the 10 new variants that demonstrated nominal evidence (p<0.05) of 
association in our study (AUC=0.61 for both weighted and unweighted sums). The ability to 
discriminate was noticeably better for the older established variants (AUC=0.69 for 
weighted sums, AUC=0.68 for unweighted sums). Adding the 23 new variants to the 40 
established variants only modestly improved the ability to discriminate (AUC=0.71 for 
weighted sums, AUC=0.69 for unweighted sums) compared to the older variants by 
themselves.
For all three sets of variants (new, established and combined) there was a steady increase, 
across decile categories, in the odds for men having PCa compared to the odds for men in 
the lowest decile grouping (Figure 2). For brevity, we focus here on results for the weighted 
total risk-allele scores (results were similar for unweighted scores (see Supplementary 
Figure 3)). A large jump in the odds ratios was observed between the highest decile group 
and the next highest decile group for the set of 40 established variants [OR = 10.50 (10th 
decile group) vs. 4.54 (9th decile group)] and combined set of 63 variants [OR = 9.63 vs. 
4.98, respectively]) (Figure 2). The odds ratios across the decile groupings for the set of new 
variants were considerably less striking than for the other sets of variants and there was no 
large jump in the last decile grouping [OR = 2.58 for the 10th decile group vs. OR = 2.49 for 
the 9th decile group]. Categorizing subjects into two groups, based on percentile cut-points 
of the total-risk-allele sums in controls, revealed that the strongest odds ratios were observed 
for both the upper and lower extreme 2.5% tail cut-points of the total-risk-score distribution 
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(see Supplementary Figure 4), consistent with the observed deficits of cases in the extreme 
lower tail and deficits of controls in the extreme upper tail of the total risk allele 
distributions.
Discussion
More than 60 independent common PCa variants have been discovered through GWAS in 
men of European ancestry. The initial discoveries, often made with relatively small case-
control samples, were made possible by the relatively strong effects (OR >1.25) of the 
associated variants. The more recent discoveries, including the 23 newly reported variants in 
Eeles et al. (20), required considerably larger sample sizes due to the associated variants 
having much smaller effects (OR~1.10). We have previously demonstrated that many of the 
older, stronger-effect, PCa variants are individually associated with early-onset PCa (21). 
Herein, we sought to assess whether there was evidence of association between early-onset 
PCa and these 23 new variants. We also evaluated the added utility of including the total 
burden of PCa risk alleles for these 23 new variants in combination with 40 previously 
established PCa variants on early-onset disease prediction. We note that we found no 
evidence supporting an association between the cumulative burden of PCa risk alleles and 
measures of disease severity including Gleason grade, tumor stage or PSA (data not shown).
We found at least nominal evidence (one-sided p<0.05; effect direction the same as the 
original study) supporting the reported associations for 10 of the 23 newly reported variants, 
including four that reached the conservative Bonferroni significance threshold. Ten of the 13 
remaining variants had directions of effect consistent with the discovery report. Thus, 
despite relatively low power to detect such replication (for example, using a one-sided 
p=0.05, we had power = 0.38 to detect an associated variant with minor allele frequency = 
0.25 and an OR = 1.10), we were able to provide supportive evidence that many of these 
variants are associated with early-onset PCa. A recent study that compared 312 hereditary 
PCa cases and 620 sporadic PCa cases to 587 common controls across these 23 variants 
found nominal evidence for association between PCa and eight of the variants for hereditary 
PCa (17/23 variants had consistent directions of effect with discovery study) and five of the 
variants for sporadic PCa (18/23 variants had consistent directions of effect) (25). No single 
variant achieved statistical significance after accounting for multiple testing in this study. 
Future larger replication studies are necessary to further validate each of these variants as a 
PCa risk variant.
The aggregate burden of risk alleles for the 23 new variants is strongly associated with early-
onset PCa, but their cumulative predictive value is relatively poor. Not surprisingly, given 
their smaller number and smaller effect sizes, their overall predictive value is considerably 
smaller than was observed for the 40 established variants. Including the burden of these 23 
variants to the burden of the 40 more established variants resulted in modestly stronger 
discrimination, with the greatest additional gains observed in men with extreme values of 
total risk-allele burden. These results suggest finding and including additional lower-effect 
common variants could be beneficial in disease prediction, but their added value will likely 
be small.
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Three previous studies have evaluated the predictive value of the cumulative burden of 
established common risk alleles for PCa diagnosis (25,32,33). The recent report by Cremers 
et al. (25) described the cumulative risk for 74 PCa variants, including the same variant or a 
strong LD proxy for 39/40 of our established variants and all 23 new variants, separately in 
312 Dutch hereditary PCa cases (mean age diagnosis 62 years) and 620 sporadic PCa cases 
(mean age diagnosis 65 years) compared to 587 common controls. Using an unweighted 
total risk allele score, Cremers et al. reported that the discriminative value based on these 74 
variants was stronger for the hereditary PCa cases [AUC=0.73] than for the sporadic PCa 
cases [AUC=0.64]. The two earlier studies limited their analyses to established variants that 
demonstrated evidence for association in their own cohorts, whereas our study and the study 
by Cremers et al. included all previously reported associated variants regardless of evidence 
in our own studies. In Lindstrom et al. (32), 23/25 variants included in their risk calculations 
were included or had a strong LD proxy among our 40 established variants. Lindstrom et al. 
showed that the predictive value of the burden of common established risk alleles was 
stronger for men diagnosed with PCa earlier in life [e.g. AUC = 0.66 using men diagnosed 
age 60 years and younger compared to AUC = 0.60 in men diagnosed after the age of 75 
years]. Agalliu et al. (33) identified 17/31 established variants that demonstrated at least 
nominal evidence for significance in a cohort of 979 PCa cases and 1,251 controls of 
Ashkenazic descent that were subsequently included in the construction of an unweighted 
total risk score (12/17 variants were included among our 40 established variants). The 
overall discriminative value of these 17 variants [AUC=0.64] was similar to the overall value 
observed by Lindstrom et al. [average AUC=0.63 across all ages for the 25 variants included 
in their study]. Consistent with Lindstrom, Agalliu et al. also observed a stronger association 
between total risk allele burden and PCa in younger cases. When comparing all men in the 
upper 25% of the total risk allele distribution to men in the lower 25%, Agalliu et al. found 
higher odds ratios in the younger men (diagnosed at age 60 years or younger; n=238) with 
PCa (OR = 5.20; 95% CI: (2.94,9.19)) than in the men diagnosed with PCa after age 60 
years (OR = 3.30; 95% CI: (2.32, 4.68)).
One very interesting feature of the distribution of total risk alleles is the lack of evidence for 
a bi-modal distribution among cases and a noticeable deficit of cases in the lower tail of the 
total risk allele distribution (see Supplementary Figures 1 and 2). The shapes of the 
distributions of total risk alleles in cases looked very similar to those of controls, with the 
distribution for the cases shifted to the right. This observation would suggest that the burden 
of common risk-alleles plays an important role in the probability of developing disease 
irrespective of other risk factors (e.g. rare variants, environmental factors, epigenetic 
factors). A widely held hypothesis is that yet to be discovered uncommon high-penetrant 
risk alleles explain a significant proportion of the increased genetic susceptibility in PCa 
families and men with early-onset disease. This hypothesis is supported by our recent 
discovery of such a mutation, G84E, in HOXB13, which has a considerably higher 
frequency in men with early-onset and/or familial disease (34). It has been reported that a 
high burden of established common variants increases disease risk even among HOXB13 
G84E carriers (35). Consistent with this report, among 23 UM-PCGP PCa HOXB13 G84E 
carriers in our study, the mean cumulative number of risk alleles across all 63 variants was 
59.10 (sd=4.88) compared to 57.99 (sd=4.92) in non-G84E-carriers.
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Disease misclassification in cases and/or controls can create biased estimates of effect. We 
note all cases in our study were confirmed by pathology report. Our controls were largely 
young males (average age 20 years) who have not, to our knowledge, been screened for PCa. 
While approximately 15% of these men will develop PCa some time in their lives, based on 
the age distribution of our cases and National Cancer Institute Surveillance, Epidemiology, 
and End Results (SEER) Program PCa prevalence rates (36), we would expect a disease 
misclassification rate of ~0.7% (n~8/1126 of our controls) using our unscreened controls 
compared to a perfectly-diagnosed age-matched control sample for our early-onset PCa case 
sample. To assess the impact of this misclassification, we recalculated the mean number of 
total risk alleles in our iControls using this misclassification rate and the observed risk allele 
counts in our cases to get an unbiased maximum-likelihood-based estimate (MLE) of mean 
total risk alleles in our control sample. Using the MLE-based estimates would decrease the 
parameter estimates for mean number of total risk alleles from 20.69 (using the uncorrected-
sample mean) to 20.68 (MLE-based mean) for the 20 new variants, 33.80 to 33.79 for the 43 
established variants, and 54.49 to 54.47 for the combined set of variants. Thus, any bias 
using these unscreened young controls, relative to age-matched controls, is expected to be 
small and result in slightly conservative conclusions. Further, we note that our expected rate 
of disease misclassification in our controls is likely lower than that for most PCa case-
control studies of older men that rely on PSA and digital rectal exam (DRE) screening. 
There is considerable overlap in distributions of PSA for men with and without PCa (37) and 
DRE screening misses Stage T1 PCa and PCa that does not occur peripherally in the 
posterior and lateral aspects of the prostate gland.
Our study includes several other features worthy of discussion. First, the iControls do not 
have available PCa family history and thus we cannot assess the additive value of PCa risk 
variants in conjunction with family history. Second, cases and controls were genotyped at 
separate times on separate, but similar, genotyping platforms. As we reported previously 
looking at >450,000 genotyped variants, we saw no evidence for systematic inflation of test 
statistics when comparing these cases to these controls (21). Still, it is possible that a small 
number of individual variants could be influenced by small genotype batch effects – though 
the direction of those batch effects would equally likely make our results conservative or 
anti-conservative, as the determination of the “risk allele” for each variant was based on 
independent data from previous reports. Third, we used imputed genotype data rather than 
directly genotyped data for analyses. Not all risk variants were directly genotyped and, when 
constructing burden scores for genotyped variants, missing data would cause unnecessary 
variation. We included only variants with high genotyping rates in both cases and controls in 
the target panel prior to genotype imputation and note that imputation quality was estimated 
to be excellent (R2>0.9) (see Table 1 and Lange et al.(21)) for the vast majority of variants. 
Fourth, a subset of patients (n=127) were directly ascertained for inclusion in linkage studies 
based on having known living relatives with disease and many other cases were symptomatic 
and identified in a hospital-based setting. Thus, this collection of 931 cases is likely not 
representative of early-onset PCa cases identified through standard epidemiological 
screening studies. Fifth, using previously reported ORs from studies based primarily on 
older men with disease, we demonstrate a small improvement in disease prediction using 
weighted total risk-allele counts compared to unweighted total risk-allele counts. Prediction 
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of early-onset disease could be improved further by applying variant weights based 
specifically on studies of early-onset disease. We note that using weights based on our own 
individual variant effect estimates in an aggregate variant burden setting would be anti-
conservative. Appropriate variant weighting for early-onset PCa aggregate risk-allele testing 
will need to be continuously refined as additional PCa populations are studied and new PCa 
variants are identified.
In summary, we provide the first significant evidence to support the association of several 
recently identified PCa variants to early-onset PCa. We establish that a high-burden of 
common risk alleles is strongly associated with early-onset PCa and that men with an 
aggregate burden of risk alleles in the tails of the total risk allele distribution have either high 
(men in the upper tail) or low (lower tail) odds of having early-onset PCa. Given the strong 
odds ratios observed in the upper tail, men with an unusually high number of risk alleles 
should be considered candidates for earlier PCa screening. The ability to discriminate 
between case-control status was largely driven by older established variants; including the 
23 new variants only modestly improved disease prediction. Despite odds ratios that were 
considerably elevated there still remained considerable overlap between the case and control 
total risk allele distributions. Given this overlap and the apparent diminishing discriminating 
value of including newly discovered lower penetrant common variants, expanding the search 
for uncommon high-penetrant risk variants could be especially critical to further improving 
our ability to accurately predict men who will get early-onset disease.
Supplementary Material
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Figure 1. 
Receiver operating characteristic curves, and corresponding area under curve (AUC), using 
weighted and unweighted burden of risk alleles for 23 new PCa variants, 40 established PCa 
variants and the 63 combined variants.
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Figure 2. 
Association between decile categories (lowest decile group is reference category) for 
weighted number of risk alleles carried and PCa. Decile-specific odds ratios were estimated 
based on the imputed dataset (931 cases and 1,126 controls) for (a) 23 newly reported PCa 
variants (b) 40 established PCa variants (c) 63 combined PCa variants.
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Table 1
Characteristics of 931 UM-PCGP early-onset PCa casesa.
Clinical Trait Mean (Standard Deviation) Median (Range)
Age at Diagnosis (years) 49.7 (4.1) 50 (27-55)
Prediagnostic PSA (mg/dL)b 20.6 (199.5) 5.2 (0.4-5428)
Gleason Score Nc %
≤ 6 410 44.6
7 427 46.4
≥ 8 83 9.0
T Stage Nd %
T1 1 0.1
T2 660 82.1
T3 140 17.4
T4 3 0.4
a
Includes 20 metastatic cases and 32 cases with lymph node involvement.
b
Prediagnostic PSA available on 870 cases.
cGleason scores available on 920 cases. Note: Prostatectomy Gleason used when available (n = 787), otherwise biopsy Gleason scores used (n = 
133).
d
T Stage available on 804 cases.
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